What is the CVR number of Allarity Therapeutics Europe ApS?

Allarity Therapeutics Europe ApS is registered with CVR / Virk under CVR 34623562.

What is the revenue of Allarity Therapeutics Europe ApS?

Allarity Therapeutics Europe ApS reported revenue of DKK -44,5M in 2024.

Allarity Therapeutics Europe ApS employs 4 people as of the latest annual report.

Jeffrey Stuart Ervin is Management of Allarity Therapeutics Europe ApS, in role since 2025.

Duncan Charles McNaught Moore chairs the board of Allarity Therapeutics Europe ApS, in role since 2015.

Allarity Therapeutics Europe ApS's registered address is Venlighedsvej 1.

APSActive

CVR 34623562Venlighedsvej 1, 2970 HørsholmManufacture of pharmaceutical preparations · NACE 2120Est. 20124 employees

Actively employed in the business

Name	Role	Member since
Current (2)
JS Jeffrey Stuart Ervin Management	Management	2025
SM Steen Meier Knudsen Chief Executive Officer	Chief Executive Officer	2023
Former (8)
TH Thomas Henrik Jensen Chief Executive Officer	Chief Executive Officer	2020 – 2021
HK Henrik Kristian Moltke Chief Executive Officer	Chief Executive Officer	2019 – 2020
AE Alexander Epshinsky Management	Management	2024 – 2025
JE Jens Erik Knudsen Management	Management	2021 – 2022
SR Stefano Roberto Carchedi Chief Executive Officer	Chief Executive Officer	2021 – 2022
PB Peter Buhl Management	Management	2012 – 2019
JG James G. Cullem Chief Executive Officer	Chief Executive Officer	2022 – 2023
JY Joan Yvonne Brown Management	Management	2022 – 2024

Non-executive oversight

Name	Role	Member since
Former (5)
JS Jørgen Søberg Petersen	Board of Directors	2015 – 2015
PB Peter Birk Rasmussen	Board of Directors	2015 – 2018
UH Ulla Hald Buhl	Board of Directors	2015 – 2018
DC Duncan Charles McNaught Moore	Chairman	2015 – 2018
CB Carani Balarman Sanjeevi	Board of Directors	2015 – 2018

As of last annual report

Shareholder	Type	Ownership	Votes	Since
Allarity Acquisition Subsidiary, Inc.	Individual	100%	100%	2021
Allarity Therapeutics A/S	Company	100%	100%	2018
SASS & LARSEN ApS	Company	15–19.99%	15–19.99%	2015
Styrelsen for Forskning og Uddannelse	Company	15–19.99%	15–19.99%	2015
Oncology Venture Sweden AB	Individual	100%	100%	2015
TIMPCO NB ApS	Company	5–9.99%	5–9.99%	2013

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.